The decision of the federal court made Amgen very happy. The federal court disputed whether to grant this patent to the company. The focus of controversy is whether the discoverer of nail gene is the original creator, that is, whether the scientists of Immunex company are the first discoverers of nail gene. The federal court finally ruled that Immunex scientist was not the first discoverer of nail gene, so it ruled that Amgen could not obtain the patent right of this gene.
The signal sent by this judgment is that the threshold for applying for genetic patents will be higher and higher in the future. Of course, the key to applying for a gene patent is whether the applicant is the first discoverer of the gene, and the identified gene sequence of protein will not be patented.